Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026, tell me about this news today

Medicenna Therapeutics announced today that topline clinical data from its Phase 1/2 ABILITY-1 study evaluating MDNA11 has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.

• Abstract Number: 517 (selected among the Top 150 Abstracts at the meeting).

  Investing.com

• Title: “MDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory Disease”.

  Investing.com

• Session & Date: Oral Session 3, Saturday, November 7, 2026, from 4:30 to 4:45 p.m. MST at the Phoenix Convention Center in Phoenix, Arizona.

  GlobeNewswire

• Trial Scope: The ABILITY-1 study evaluates MDNA11 both as a monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced and metastatic solid tumors, with a focus on expansion cohorts in gastrointestinal, endometrial, and melanoma cancers.

  Investing.com

• Focus Area: The presentation highlights clinical activity in biomarker-enriched gastrointestinal malignancies, specifically demonstrating therapeutic impact in difficult-to-treat patients who are refractory to prior immune checkpoint inhibitor (ICI) therapies.

MDNA11 is Medicenna’s investigational, long-acting “beta-enhanced not-alpha” IL-2 Superkine. It is engineered to overcome the severe toxicities of native IL-2 (aldesleukin) by selectively binding CD122 (IL-2Rβ) to activate tumor-killing CD8+ T and natural killer (NK) cells, while avoiding CD25 (IL-2Rα) to minimize stimulation of immunosuppressive regulatory T cells (Tregs) and reduce vascular leak syndrome.